CN106619886A - 含毛茛草提取物的治疗肝炎的中西药组合物及其制备方法 - Google Patents
含毛茛草提取物的治疗肝炎的中西药组合物及其制备方法 Download PDFInfo
- Publication number
- CN106619886A CN106619886A CN201611117904.8A CN201611117904A CN106619886A CN 106619886 A CN106619886 A CN 106619886A CN 201611117904 A CN201611117904 A CN 201611117904A CN 106619886 A CN106619886 A CN 106619886A
- Authority
- CN
- China
- Prior art keywords
- parts
- buttercup
- chinese
- grass
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims abstract description 126
- 239000000203 mixture Substances 0.000 title claims abstract description 110
- 241000218206 Ranunculus Species 0.000 title claims abstract description 92
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 46
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 43
- 239000002994 raw material Substances 0.000 claims abstract description 31
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960003174 lansoprazole Drugs 0.000 claims abstract description 28
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 19
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 19
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 19
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 19
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 19
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 19
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 19
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 19
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 244000025254 Cannabis sativa Species 0.000 claims description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 18
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 18
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 18
- 241000725605 Pilea notata Species 0.000 claims description 18
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 18
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 18
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 18
- 210000000003 hoof Anatomy 0.000 claims description 18
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- 239000000341 volatile oil Substances 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 238000005057 refrigeration Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 235000010388 propyl gallate Nutrition 0.000 claims description 4
- 239000000473 propyl gallate Substances 0.000 claims description 4
- 229940075579 propyl gallate Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 240000002853 Nelumbo nucifera Species 0.000 claims description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 240000006927 Foeniculum vulgare Species 0.000 claims 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims 1
- -1 butylhydroxy Chemical group 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 241001149422 Ganoderma applanatum Species 0.000 abstract 1
- 241001106412 Pilea Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 abstract 1
- 229910052603 melanterite Inorganic materials 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 230000037396 body weight Effects 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 150000003851 azoles Chemical class 0.000 description 6
- 238000005202 decontamination Methods 0.000 description 6
- 230000003588 decontaminative effect Effects 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 3
- 101710142246 External core antigen Proteins 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 3
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 231100000838 cholestatic hepatitis Toxicity 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种含毛茛草提取物的治疗肝炎的中西药组合物及其制备方法，由以下重量份的原料组成：兰索拉唑、毛茛草提取物、中药浸膏粉；所述中药浸膏粉由以下重量份的原料组成：树舌、煅青凡、当归、竹黄、绵茵陈、木蹄、土鳖虫、牡丹皮、半枝莲、桃仁、炙甘草、虎杖、冷水花、柴胡。本发明能够缩短疗程、增强疗效，采用兰索拉唑、毛茛草提取物和中药浸膏粉为原料，即将中医药结合起来，起到协同作用，解决了西药和中药在辅助治疗各种类型肝炎中各自存在的问题，同时产生协同治疗效果。
Description
技术领域
本发明涉及一种药物，具体是一种含毛茛草提取物的治疗肝炎的中西药组合物及其制备方法。
背景技术
肝炎在临床上有多种分类方法，如(1)病原学分类：可将病毒性肝炎分为五型即甲、乙、丙、丁、戊。(2)临床分类可分为以下儿型：①急性无黄疸型肝炎，这是病毒性肝炎中最常见的类烈，以乙烈、丙烈、丁烈肝炎多见，一般此类肝炎临床症状较少，转氨酶升高水平较低，组织学改变轻，死亡率较低，但病程可迁延较长时间，有“三慢”特点，发病慢、恢复慢、迁延也慢(慢指长的意思)；②急性黄疸型肝炎，比起无黄疸型肝炎来说相对较少，病情常为自限性，预后多良好，但少数可发展成重型肝炎；③慢性肝炎：1994年有关专家又提出慢性肝炎的命名与建议，以病原为基础确定慢性肝炎的诊断命名，同时根据肝炎炎症的坏死严重程度订了分级标准，又根据肝纤维化程度制定了分期标准；④重型肝炎，又可分为急性重型、亚急性重型和慢性重型；⑤淤胆型肝炎。
目前用于治疗急慢性肝损害的药物，较常用的有葡醛内酯、甘草酸二按等。这些化学药物普遍有一定的副作用，并导致远期治疗效果差、病毒株产生耐药现象、停药后复发率高等问题。
中医药治疗乙肝的疗效已被大量的临床试验所证明。中药在抗病毒、调节机体免疫力、保护肝细胞等方面都可发挥较好的疗效。但是目前中药制剂普遍存在起效缓慢，需要长期使用等问题。
毛茛草生命力旺盛，愈合能力强。喜温暖湿润和阳光充足环境，较耐寒，不耐高温和干旱，但耐水淹，萌发力强，枝条密集。在深水区域及河岸上没有毛茛草生长，在河谷滨水区域分布最多，且生长最旺盛；毛茛草中含有果胶8.5％，树皮含鞣质，在球状花果序中还分出熊果酸、β-谷甾醇、土当归酸等。花、果序经预试含儿茶素类化合物；能够清热解毒，散瘀止痛。
目前尚无单独使用毛茛草或其提取物与西药配合治疗胃溃疡的相关报道。
发明内容
本发明的目的在于提供一种安全可靠、疗效确切的含毛茛草提取物的治疗肝炎的中西药组合物及其制备方法，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种含毛茛草提取物的治疗肝炎的中西药组合物，由以下重量份的原料组成：兰索拉唑3-5份、毛茛草提取物2-4份、中药浸膏粉10-20份；所述中药浸膏粉由以下重量份的原料组成：树舌20-30份、煅青凡20-40份、当归5-10份、竹黄6-8份、绵茵陈6-10份、木蹄3-5份、土鳖虫1-3份、牡丹皮2-4份、半枝莲6-8份、桃仁4-6份、炙甘草3-5份、虎杖1-3份、冷水花1-2份、柴胡1-2份。
作为本发明进一步的方案：所述含毛茛草提取物的治疗肝炎的中西药组合物，由以下重量份的原料组成：兰索拉唑3.5-4.5份、毛茛草提取物2.5-3.5份、中药浸膏粉12-18份；所述中药浸膏粉由以下重量份的原料组成：树舌22-28份、煅青凡25-35份、当归6-9份、竹黄6.5-7.5份、绵茵陈7-9份、木蹄3.5-4.5份、土鳖虫1.5-2.5份、牡丹皮2.5-3.5份、半枝莲6.5-7.5份、桃仁4.5-5.5份、炙甘草3.5-4.5份、虎杖1.5-2.5份、冷水花1.2-1.8份、柴胡1.2-1.8份。
作为本发明进一步的方案：所述含毛茛草提取物的治疗肝炎的中西药组合物，由以下重量份的原料组成：兰索拉唑4份、毛茛草提取物3份、中药浸膏粉15份；所述中药浸膏粉由以下重量份的原料组成：树舌25份、煅青凡30份、当归8份、竹黄7份、绵茵陈8份、木蹄7份、土鳖虫2份、牡丹皮3份、半枝莲7份、桃仁5份、炙甘草4份、虎杖2份、冷水花1.5份、柴胡1.5份。
作为本发明进一步的方案：所述毛茛草提取物毛茛草水提取物或毛茛草挥发油、或毛茛草水提取物和毛茛草挥发油的混合物。
作为本发明进一步的方案：所述的混合物是由毛茛草提取物、毛茛草挥发油为活性成分按下述重量配比制备而成：毛茛草提取物1.8-3.5份、毛茛草挥发油0.2-0.5份。
作为本发明进一步的方案：所述的混合物是由毛茛草提取物、毛茛草挥发油为活性成分按下述重量配比制备而成：毛茛草提取物2.7份、毛茛草挥发油0.3份。
所述含毛茛草提取物的治疗肝炎的中西药组合物的制备方法，具体步骤如下：
(1)按照重量份称取各原料；
(2)按配方称取新鲜的半枝莲、炙甘草和冷水花，入榨机榨出汁液，冷藏，过滤，除去杂质和沉淀，脱色处理，浓缩至含水量为45-55％，再加入0.1-0.2％的抗氧化剂，得到纯净药液，为成分A备用；
(3)按配方称取树舌、煅青凡、当归、竹黄、绵茵陈、木蹄、土鳖虫、牡丹皮、虎杖、柴胡、桃仁、分别制成中药饮片，粉碎后过50-60目筛，加相对于所获得的混合物4-6倍重量的纯净水，浸泡10-14h，再加入3-4倍重量的纯净水，置于锅炉中煎煮提取1-3次，每次提取0.5-1h，过滤，合并滤液得到成分B备用；
(4)将成分A和成分B混合均匀后浓缩成稠膏，再喷雾干燥得到中药浸膏粉；
(5)将兰索拉唑、毛茛草提取物和中药浸膏粉混合后制成中西药组合物制剂。
作为本发明进一步的方案：所述抗氧化剂为抗坏血酸棕搁酸酯、没食子酸丙酯、焦亚硫酸钠、丁基羟基茴香醚中的一种或几种。
作为本发明进一步的方案：所述中西药组合物制剂为片剂、胶囊或颗粒剂。
作为本发明再进一步的方案：所述中西药组合物在制备治疗肝炎药物中的应用。
药理作用研究：
木发明药用组合物的主要药效学研究证实了其具有较强降低转氨酶作用，即保肝降酶作用。
参照张均田主编，《现代药理试验方法》(下册)，北京医科大学中国协和医科大学联合出版社，第1397-1398页，“第一节小鼠急性化学性肝损伤模型”中公开的方法，建立小鼠四氯化碳急性化学肝损伤模型，进行本发明的药用组合物抗肝损伤的药效学试验。
试验分组：
(1)正常对照组：动物未作任何处理，正常生理盐水灌胃；
(2)模型对照组：动物模型造模成功后，正常生理盐水灌胃；
(3)纯中药组：如上文所述的中药浸膏粉0.45g/kg体重灌胃；
(4)兰索拉唑组：如上文所述的兰索拉唑9mg/kg体重灌胃；
(5)毛茛草提取物组：如上文所述的毛茛草提取物9mg/kg体重灌胃；
(6)兰索拉唑和毛茛草提取物混合物组：4.5mg/kg体重兰索拉唑+4.5mg/kg体重各采用灌胃；
(7)中西药组合物组：4.5mg/kg体重兰索拉唑+4.5mg/kg体重毛茛草提取物+0.45g/kg体重中药浸膏粉灌胃。
下表显示了各组对小鼠肝功能主要指标GOT、GPT的影响。
表1：各组对小鼠肝功能主要指标GOT、GPT的影响
| 组别 | 动物数 | GOT(活性单位) | GPT(活性单位) |
| 正常对照组 | 10 | 22.43±12.69 | 51.78±16.98 |
| 模型对照组 | 10 | 256.78±72.54 | 318.74±58.42 |
| 纯中药组 | 10 | 188.76±66.31 | 221.41±55.97 |
| 兰索拉唑组 | 10 | 127.32±56.53 | 196.38±25.11 |
| 毛茛草提取物组 | 10 | 134.12±79.45 | 186.47±26.13 |
| 兰索拉唑和毛茛草提取物混合物组 | 10 | 158.63±72.18 | 190.43±29.72 |
| 中西药组合物组 | 10 | 81.22±21.29 | 102.01±28.64 |
该表显示治疗各组(纯中药组、兰索拉唑组、毛茛草提取物组、兰索拉唑和毛茛草提取物混合物组、中西药组合物组)均与模型对照组存在显著性差异(P＜0.05)，而中西药组合物组与纯中药组、中西药组合物组与兰索拉唑组、中西药组合物组与毛茛草提取物组、中西药组合物组与兰索拉唑和毛茛草提取物混合物组均存在显著性差异(P＜0.05)。显示组合物组中的兰索拉唑、毛茛草提取物与中药组分相互之间存在协同效应。
与现有技术相比，本发明的有益效果是：
本发明能够缩短疗程、增强疗效，采用兰索拉唑、毛茛草提取物和中药浸膏粉为原料，即将中医药结合起来，起到协同作用，解决了西药和中药在辅助治疗各种类型肝炎中各自存在的问题，同时产生协同治疗效果。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种含毛茛草提取物的治疗肝炎的中西药组合物，由以下重量份的原料组成：兰索拉唑3份、毛茛草提取物2份、中药浸膏粉10份；所述中药浸膏粉由以下重量份的原料组成：树舌20份、煅青凡20份、当归5份、竹黄6份、绵茵陈6份、木蹄3份、土鳖虫1份、牡丹皮2份、半枝莲6份、桃仁4份、炙甘草3份、虎杖1份、冷水花1份、柴胡1份。
所述含毛茛草提取物的治疗肝炎的中西药组合物的制备方法，具体步骤如下：
(1)按照重量份称取各原料；
(2)按配方称取新鲜的半枝莲、炙甘草和冷水花，入榨机榨出汁液，冷藏，过滤，除去杂质和沉淀，脱色处理，浓缩至含水量为45％，再加入0.1％的抗氧化剂，得到纯净药液，为成分A备用；
(3)按配方称取树舌、煅青凡、当归、竹黄、绵茵陈、木蹄、土鳖虫、牡丹皮、虎杖、柴胡、桃仁、分别制成中药饮片，粉碎后过50目筛，加相对于所获得的混合物4倍重量的纯净水，浸泡10h，再加入3倍重量的纯净水，置于锅炉中煎煮提取1次，每次提取0.5h，过滤，合并滤液得到成分B备用；
(4)将成分A和成分B混合均匀后浓缩成稠膏，再喷雾干燥得到中药浸膏粉；
(5)将兰索拉唑、毛茛草提取物和中药浸膏粉混合后制成中西药组合物制剂。
实施例2
一种含毛茛草提取物的治疗肝炎的中西药组合物，由以下重量份的原料组成：兰索拉唑3.5份、毛茛草提取物2.5份、中药浸膏粉12份；所述中药浸膏粉由以下重量份的原料组成：树舌22份、煅青凡25份、当归6份、竹黄6.5份、绵茵陈7份、木蹄3.5份、土鳖虫1.5份、牡丹皮2.5份、半枝莲6.5份、桃仁4.5份、炙甘草3.5份、虎杖1.5份、冷水花1.2份、柴胡1.2份。
所述含毛茛草提取物的治疗肝炎的中西药组合物的制备方法，具体步骤如下：
(1)按照重量份称取各原料；
(2)按配方称取新鲜的半枝莲、炙甘草和冷水花，入榨机榨出汁液，冷藏，过滤，除去杂质和沉淀，脱色处理，浓缩至含水量为48％，再加入0.12％的抗氧化剂，得到纯净药液，为成分A备用；
(3)按配方称取树舌、煅青凡、当归、竹黄、绵茵陈、木蹄、土鳖虫、牡丹皮、虎杖、柴胡、桃仁、分别制成中药饮片，粉碎后过52目筛，加相对于所获得的混合物4.5倍重量的纯净水，浸泡11h，再加入3.2重量的纯净水，置于锅炉中煎煮提取2次，每次提取0.6h，过滤，合并滤液得到成分B备用；
(4)将成分A和成分B混合均匀后浓缩成稠膏，再喷雾干燥得到中药浸膏粉；
(5)将兰索拉唑、毛茛草提取物和中药浸膏粉混合后制成中西药组合物制剂。
作为本发明进一步的方案：所述抗氧化剂为抗坏血酸棕搁酸酯、没食子酸丙酯、焦亚硫酸钠、丁基羟基茴香醚中的一种或几种。
实施例3
所述含毛茛草提取物的治疗肝炎的中西药组合物，由以下重量份的原料组成：兰索拉唑4份、毛茛草提取物3份、中药浸膏粉15份；所述中药浸膏粉由以下重量份的原料组成：树舌25份、煅青凡30份、当归8份、竹黄7份、绵茵陈8份、木蹄7份、土鳖虫2份、牡丹皮3份、半枝莲7份、桃仁5份、炙甘草4份、虎杖2份、冷水花1.5份、柴胡1.5份。
所述含毛茛草提取物的治疗肝炎的中西药组合物的制备方法，具体步骤如下：
(1)按照重量份称取各原料；
(2)按配方称取新鲜的半枝莲、炙甘草和冷水花，入榨机榨出汁液，冷藏，过滤，除去杂质和沉淀，脱色处理，浓缩至含水量为50％，再加入0.15％的抗氧化剂，得到纯净药液，为成分A备用；
(3)按配方称取树舌、煅青凡、当归、竹黄、绵茵陈、木蹄、土鳖虫、牡丹皮、虎杖、柴胡、桃仁、分别制成中药饮片，粉碎后过55目筛，加相对于所获得的混合物5倍重量的纯净水，浸泡12h，再加入3.5倍重量的纯净水，置于锅炉中煎煮提取2次，每次提取0.8h，过滤，合并滤液得到成分B备用；
(4)将成分A和成分B混合均匀后浓缩成稠膏，再喷雾干燥得到中药浸膏粉；
(5)将兰索拉唑、毛茛草提取物和中药浸膏粉混合后制成中西药组合物制剂。
实施例4
一种含毛茛草提取物的治疗肝炎的中西药组合物，由以下重量份的原料组成：兰索拉唑4.5份、毛茛草提取物3.5份、中药浸膏粉18份；所述中药浸膏粉由以下重量份的原料组成：树舌28份、煅青凡35份、当归9份、竹黄7.5份、绵茵陈9份、木蹄4.5份、土鳖虫2.5份、牡丹皮3.5份、半枝莲7.5份、桃仁5.5份、炙甘草4.5份、虎杖2.5份、冷水花1.8份、柴胡1.8份。
所述含毛茛草提取物的治疗肝炎的中西药组合物的制备方法，具体步骤如下：
(1)按照重量份称取各原料；
(2)按配方称取新鲜的半枝莲、炙甘草和冷水花，入榨机榨出汁液，冷藏，过滤，除去杂质和沉淀，脱色处理，浓缩至含水量为52％，再加入0.18％的抗氧化剂，得到纯净药液，为成分A备用；
(3)按配方称取树舌、煅青凡、当归、竹黄、绵茵陈、木蹄、土鳖虫、牡丹皮、虎杖、柴胡、桃仁、分别制成中药饮片，粉碎后过58目筛，加相对于所获得的混合物5.5倍重量的纯净水，浸泡13h，再加入3.8重量的纯净水，置于锅炉中煎煮提取3次，每次提取0.9h，过滤，合并滤液得到成分B备用；
(4)将成分A和成分B混合均匀后浓缩成稠膏，再喷雾干燥得到中药浸膏粉；
(5)将兰索拉唑、毛茛草提取物和中药浸膏粉混合后制成中西药组合物制剂。
作为本发明进一步的方案：所述抗氧化剂为抗坏血酸棕搁酸酯、没食子酸丙酯、焦亚硫酸钠、丁基羟基茴香醚中的一种或几种。
实施例5
一种含毛茛草提取物的治疗肝炎的中西药组合物，由以下重量份的原料组成：兰索拉唑5份、毛茛草提取物4份、中药浸膏粉20份；所述中药浸膏粉由以下重量份的原料组成：树舌30份、煅青凡40份、当归10份、竹黄8份、绵茵陈10份、木蹄5份、土鳖虫3份、牡丹皮4份、半枝莲8份、桃仁6份、炙甘草5份、虎杖3份、冷水花2份、柴胡2份。
所述含毛茛草提取物的治疗肝炎的中西药组合物的制备方法，具体步骤如下：
(1)按照重量份称取各原料；
(2)按配方称取新鲜的半枝莲、炙甘草和冷水花，入榨机榨出汁液，冷藏，过滤，除去杂质和沉淀，脱色处理，浓缩至含水量为55％，再加入0.2％的抗氧化剂，得到纯净药液，为成分A备用；
(3)按配方称取树舌、煅青凡、当归、竹黄、绵茵陈、木蹄、土鳖虫、牡丹皮、虎杖、柴胡、桃仁、分别制成中药饮片，粉碎后过60目筛，加相对于所获得的混合物6倍重量的纯净水，浸泡14h，再加入4倍重量的纯净水，置于锅炉中煎煮提取3次，每次提取1h，过滤，合并滤液得到成分B备用；
(4)将成分A和成分B混合均匀后浓缩成稠膏，再喷雾干燥得到中药浸膏粉；
(5)将兰索拉唑、毛茛草提取物和中药浸膏粉混合后制成中西药组合物制剂。
实施例6
实施例3制备的含毛茛草提取物的治疗肝炎的中西药组合物对HbsAg和HbeAg两种抗原的分泌的抑制作用试验：
将对数生长期的HepG2.2.15按104/ml接种于96孔细胞培养板中，每孔180μl；待细胞贴壁后(24h)加药，实验分为5个小组，(1)中西药组合物组：600、300、150、75mg/L；(2)空白对照组：8％FBS的RPMI1640培养基；37℃，5％CO2分别孵育60h、84h后测定培养基上清液中HBsAg与HBeAg的表达。
试验表明：本发明中西药组合物对HBsAg和HBeAg两种抗原的分泌均有抑制作用，且在实验的84h达高峰。说明本发明中西药组合物抗乙肝作用确切而且毒性较低。
表2：本发明的中西药组合物对HepG2.2.15细胞株HBsAg分泌的影响(n＝3，x±s)
*P<0.05**P<0.01。
表3：本发明的中西药组合物对HepG2.2.15细胞株HBeAg分泌的影响(n＝3，x±s)
*P<0.05**P<0.01
本发明能够缩短疗程、增强疗效，采用兰索拉唑、毛茛草提取物和中药浸膏粉为原料，即将中医药结合起来，起到协同作用，解决了西药和中药在辅助治疗各种类型肝炎中各自存在的问题，同时产生协同治疗效果。
上面对本专利的较佳实施方式作了详细说明，但是本专利并不限于上述实施方式，在本领域的普通技术人员所具备的知识范围内，还可以在不脱离本专利宗旨的前提下作出各种变化。
Claims (10)
1.一种含毛茛草提取物的治疗肝炎的中西药组合物，其特征在于，由以下重量份的原料组成：兰索拉唑3-5份、毛茛草提取物2-4份、中药浸膏粉10-20份；所述中药浸膏粉由以下重量份的原料组成：树舌20-30份、煅青凡20-40份、当归5-10份、竹黄6-8份、绵茵陈6-10份、木蹄3-5份、土鳖虫1-3份、牡丹皮2-4份、半枝莲6-8份、桃仁4-6份、炙甘草3-5份、虎杖1-3份、冷水花1-2份、柴胡1-2份。
2.根据权利要求1所述的含毛茛草提取物的治疗肝炎的中西药组合物，其特征在于，由以下重量份的原料组成：兰索拉唑3.5-4.5份、毛茛草提取物2.5-3.5份、中药浸膏粉12-18份；所述中药浸膏粉由以下重量份的原料组成：树舌22-28份、煅青凡25-35份、当归6-9份、竹黄6.5-7.5份、绵茵陈7-9份、木蹄3.5-4.5份、土鳖虫1.5-2.5份、牡丹皮2.5-3.5份、半枝莲6.5-7.5份、桃仁4.5-5.5份、炙甘草3.5-4.5份、虎杖1.5-2.5份、冷水花1.2-1.8份、柴胡1.2-1.8份。
3.根据权利要求1所述的含毛茛草提取物的治疗肝炎的中西药组合物，其特征在于，由以下重量份的原料组成：兰索拉唑4份、毛茛草提取物3份、中药浸膏粉15份；所述中药浸膏粉由以下重量份的原料组成：树舌25份、煅青凡30份、当归8份、竹黄7份、绵茵陈8份、木蹄7份、土鳖虫2份、牡丹皮3份、半枝莲7份、桃仁5份、炙甘草4份、虎杖2份、冷水花1.5份、柴胡1.5份。
4.根据权利要求1-3任一所述的含毛茛草提取物的治疗肝炎的中西药组合物，其特征在于，所述毛茛草提取物毛茛草水提取物或毛茛草挥发油、或毛茛草水提取物和毛茛草挥发油的混合物。
5.根据权利要求4所述的含毛茛草提取物的治疗肝炎的中西药组合物，其特征在于，所述的混合物是由毛茛草提取物、毛茛草挥发油为活性成分按下述重量配比制备而成：毛茛草提取物1.8-3.5份、毛茛草挥发油0.2-0.5份。
6.根据权利要求4所述的含毛茛草提取物的治疗肝炎的中西药组合物，其特征在于，所述的混合物是由毛茛草提取物、毛茛草挥发油为活性成分按下述重量配比制备而成：毛茛草提取物2.7份、毛茛草挥发油0.3份。
7.一种如权利要求1-3任一所述的含毛茛草提取物的治疗肝炎的中西药组合物的制备方法，其特征在于，具体步骤如下：
(1)按照重量份称取各原料；
(2)按配方称取新鲜的半枝莲、炙甘草和冷水花，入榨机榨出汁液，冷藏，过滤，除去杂质和沉淀，脱色处理，浓缩至含水量为45-55％，再加入0.1-0.2％的抗氧化剂，得到纯净药液，为成分A备用；
(3)按配方称取树舌、煅青凡、当归、竹黄、绵茵陈、木蹄、土鳖虫、牡丹皮、虎杖、柴胡、桃仁、分别制成中药饮片，粉碎后过50-60目筛，加相对于所获得的混合物4-6倍重量的纯净水，浸泡10-14h，再加入3-4倍重量的纯净水，置于锅炉中煎煮提取1-3次，每次提取0.5-1h，过滤，合并滤液得到成分B备用；
(4)将成分A和成分B混合均匀后浓缩成稠膏，再喷雾干燥得到中药浸膏粉；
(5)将兰索拉唑、毛茛草提取物和中药浸膏粉混合后制成中西药组合物制剂。
8.根据权利要求7所述的含毛茛草提取物的治疗肝炎的中西药组合物的制备方法，其特征在于，所述抗氧化剂为抗坏血酸棕搁酸酯、没食子酸丙酯、焦亚硫酸钠、丁基羟基茴香醚中的一种或几种。
9.根据权利要求7所述的含毛茛草提取物的治疗肝炎的中西药组合物的制备方法，其特征在于，所述中西药组合物制剂为片剂、胶囊或颗粒剂。
10.一种如权利要求1-3任一所述的中西药组合物在制备治疗肝炎药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611117904.8A CN106619886A (zh) | 2016-12-07 | 2016-12-07 | 含毛茛草提取物的治疗肝炎的中西药组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611117904.8A CN106619886A (zh) | 2016-12-07 | 2016-12-07 | 含毛茛草提取物的治疗肝炎的中西药组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619886A true CN106619886A (zh) | 2017-05-10 |
Family
ID=58819928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611117904.8A Withdrawn CN106619886A (zh) | 2016-12-07 | 2016-12-07 | 含毛茛草提取物的治疗肝炎的中西药组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619886A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114209844A (zh) * | 2022-01-27 | 2022-03-22 | 中以海德人工智能药物研发股份有限公司 | 一种用于治疗病毒性肝炎的药物组合物 |
| CN114224888A (zh) * | 2021-01-03 | 2022-03-25 | 中以海德人工智能药物研发股份有限公司 | 兰索拉唑在制备治疗或预防病毒性肝炎用药物中的用途 |
| CN114515338A (zh) * | 2022-03-04 | 2022-05-20 | 中以海德人工智能药物研发股份有限公司 | 一种用于治疗病毒性肝炎的药物组合物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899578A (zh) * | 2006-07-06 | 2007-01-24 | 汪甬伟 | 辅助治疗肝炎的药物 |
-
2016
- 2016-12-07 CN CN201611117904.8A patent/CN106619886A/zh not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899578A (zh) * | 2006-07-06 | 2007-01-24 | 汪甬伟 | 辅助治疗肝炎的药物 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114224888A (zh) * | 2021-01-03 | 2022-03-25 | 中以海德人工智能药物研发股份有限公司 | 兰索拉唑在制备治疗或预防病毒性肝炎用药物中的用途 |
| CN114209844A (zh) * | 2022-01-27 | 2022-03-22 | 中以海德人工智能药物研发股份有限公司 | 一种用于治疗病毒性肝炎的药物组合物 |
| CN114515338A (zh) * | 2022-03-04 | 2022-05-20 | 中以海德人工智能药物研发股份有限公司 | 一种用于治疗病毒性肝炎的药物组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632827B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| CN103330865B (zh) | 一种治疗非酒精性脂肪性肝炎的药物及制备方法 | |
| CN106619886A (zh) | 含毛茛草提取物的治疗肝炎的中西药组合物及其制备方法 | |
| CN107007696B (zh) | 一种治疗重症急性胰腺炎或不全性肠梗阻的中药复方灌肠制剂 | |
| CN103223069A (zh) | 一种治疗肝炎的中药组合物 | |
| CN103784890A (zh) | 一种治疗骨病的中药组合物 | |
| CN103599495A (zh) | 一种治疗乙肝的中药组合物 | |
| CN101933973B (zh) | 防治肝损伤的药物组合物 | |
| CN102935133A (zh) | 一种用于治疗风湿性关节炎的中药组合物及其制备方法和应用 | |
| CN104435977B (zh) | 一种用于治疗肝损伤的药物及其制备方法 | |
| CN107029173B (zh) | 一种治疗原发性肝癌的药物组合物 | |
| CN102652819B (zh) | 一种妇炎康分散片及其制备方法 | |
| CN104435567A (zh) | 一种含绞股蓝的治疗痛风的中药组合物 | |
| CN104189473A (zh) | 一种治疗结核病的药物组合物及其制备方法 | |
| CN103463247A (zh) | 一种治疗肝炎转氨酶增高的中药及其制备方法 | |
| CN1686424A (zh) | 一种含有黄芩和柴胡的药物组合物及其制备方法 | |
| CN103055289B (zh) | 一种治疗恶性淋巴瘤的中药组合物及其制备方法 | |
| CN106728117A (zh) | 含毛茛草提取物的治疗肝炎的中西药组合物 | |
| CN106491916A (zh) | 含水杨梅提取物的治疗肝炎的中西药组合物及其制备方法 | |
| CN104435079A (zh) | 一种治疗痛风的中药组合物 | |
| CN106728722A (zh) | 含水杨梅提取物的治疗肝炎的中西药组合物 | |
| CN106491991A (zh) | 含水杨梅提取物的治疗慢性肝炎的中西药组合物及其制备方法 | |
| CN106692694A (zh) | 含毛茛草提取物的治疗肝硬化的中西药组合物及其制备方法 | |
| CN105998244A (zh) | 一种用于慢性心衰的中药制剂 | |
| CN106620380A (zh) | 一种防治畜禽病毒性疾病的中药饲料添加剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170510 |
|
| WW01 | Invention patent application withdrawn after publication |